1-9 of 9
Adil I. Daud
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Liver–Immunity Nexus and Cancer Immunotherapy

James C. Lee, Michael D. Green, Laura A. Huppert, Christine Chow, Robert H. Pierce, Adil I. Daud
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 5–12.
https://doi.org/10.1158/1078-0432.CCR-21-1193
Published: 05 January 2022
View article titled, The Liver–Immunity Nexus and Cancer Immunotherapy
Open the PDF for The Liver–Immunity Nexus and Cancer Immunotherapy in another window
Journal Articles

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Alain P. Algazi, Christopher G. Twitty, Katy K. Tsai, Mai Le, Robert Pierce, Erica Browning, Reneta Hermiz, David A. Canton, Donna Bannavong, Arielle Oglesby, Murray Francisco, Lawrence Fong, Mikael J. Pittet, Sean P. Arlauckas, Christopher Garris, Lauren P. Levine, Carlos Bifulco, Carmen Ballesteros-Merino, Shailender Bhatia, Sharron Gargosky, Robert H.I. Andtbacka, Bernard A. Fox, Michael D. Rosenblum, Adil I. Daud
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2827–2837.
https://doi.org/10.1158/1078-0432.CCR-19-2217
Published: 15 June 2020
View article titled, Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Open the PDF for Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma in another window
Includes: Supplementary data
Journal Articles

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma

Shailender Bhatia, Natalie V. Longino, Natalie J. Miller, Rima Kulikauskas, Jayasri G. Iyer, Dafina Ibrani, Astrid Blom, David R. Byrd, Upendra Parvathaneni, Christopher G. Twitty, Jean S. Campbell, Mai H. Le, Sharron Gargosky, Robert H. Pierce, Richard Heller, Adil I. Daud, Paul Nghiem
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 598–607.
https://doi.org/10.1158/1078-0432.CCR-19-0972
Published: 03 February 2020
View article titled, Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma
Open the PDF for Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, David L. Rimm, Thai H. Ho, Richard W. Joseph, Adil I. Daud, Robert M. Conry, Elizabeth M. Gaughan, Leonel F. Hernandez-Aya, Anastasios Dimou, Pauline Funchain, James Smithy, John S. Witte, Svetlana B. McKee, Jennifer Ko, John M. Wrangle, Bashar Dabbas, Shabnam Tangri, Jelveh Lameh, Jeffrey Hall, Joseph Markowitz, Justin M. Balko, Naveen Dakappagari
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (21): 5250–5260.
https://doi.org/10.1158/1078-0432.CCR-18-0309
Published: 01 November 2018
View article titled, Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
Open the PDF for Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

Adil I. Daud, Smitha S. Krishnamurthi, Mansoor N. Saleh, Barbara J. Gitlitz, Mitesh J. Borad, Philip J. Gold, Elena G. Chiorean, Gregory M. Springett, Richat Abbas, Shefali Agarwal, Nathalie Bardy-Bouxin, Poe-Hirr Hsyu, Eric Leip, Kathleen Turnbull, Charles Zacharchuk, Wells A. Messersmith
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1092–1100.
https://doi.org/10.1158/1078-0432.CCR-11-2378
Published: 14 February 2012
View article titled, Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

Mayer N. Fishman, John A. Thompson, Gregory K. Pennock, Rene Gonzalez, Luz M. Diez, Adil I. Daud, Jeffery S. Weber, Bee Y. Huang, Shamay Tang, Peter R. Rhode, Hing C. Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7765–7775.
https://doi.org/10.1158/1078-0432.CCR-11-1817
Published: 18 December 2011
View article titled, Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
Open the PDF for Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies in another window
Journal Articles

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Adil I. Daud, Jana Dawson, Ronald C. DeConti, Elona Bicaku, Douglas Marchion, Sem Bastien, Frederick A. Hausheer, III, Richard Lush, Anthony Neuger, Daniel M. Sullivan, Pamela N. Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2479–2487.
https://doi.org/10.1158/1078-0432.CCR-08-1931
Published: 01 April 2009
View article titled, Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Open the PDF for Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

Jade Homsi, George R. Simon, Chris R. Garrett, Gregory Springett, Ronald De Conti, Alberto A. Chiappori, Pamela N. Munster, Michelle K. Burton, Scott Stromatt, Claudia Allievi, Patrizia Angiuli, Amy Eisenfeld, Daniel M. Sullivan, Adil I. Daud
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5855–5861.
https://doi.org/10.1158/1078-0432.CCR-06-2821
Published: 01 October 2007
View article titled, Phase I Trial of Poly-<sc>l</sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
Open the PDF for Phase I Trial of Poly-<sc>l</sc>-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies in another window
Journal Articles

Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ

Douglas C. Marchion, Elona Bicaku, Joel G. Turner, Adil I. Daud, Daniel M. Sullivan, Pamela N. Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8467–8475.
https://doi.org/10.1158/1078-0432.CCR-05-1073
Published: 01 December 2005
View article titled, Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ
Open the PDF for Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ in another window